Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis (STOPGAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04762953
Recruitment Status : Recruiting
First Posted : February 21, 2021
Last Update Posted : March 9, 2021
Information provided by (Responsible Party):
Maheswari Senthil, MD, University of California, Irvine

Brief Summary:
This is a phase II clinical trial assessing the safety and efficacy of sequential systemic and intraperitoneal (IP) chemotherapy in patients with primary gastric/gastroesophageal junction cancer with cytology positive peritoneal lavage and/or peritoneal carcinomatosis.

Condition or disease Intervention/treatment Phase
Gastric Cancer Peritoneal Carcinomatosis Gastroesophageal Junction Adenocarcinoma Drug: Paclitaxel Drug: Leucovorin Drug: Fluorouracil Phase 2

Detailed Description:
Patients with histologically proven primary gastric or gastroesophageal junction (Siewert 3) adenocarcinoma with positive peritoneal cytology or peritoneal carcinomatosis detected by laparoscopy, laparotomy or imaging and without evidence of distant organ metastasis will be eligible for this study. Patients will undergo systemic therapy for 3-4 months at the discretion of the medical oncologist based on molecular makers (PD-L1, HER -2 neu, MSI). Patients without distant organ metastatic progression after completion of systemic chemotherapy, will undergo diagnostic laparoscopy and IP port placement. IP regimen will consist of IV Paclitaxel, 5- FU and Leucovorin and IP Paclitaxel. Paclitaxel 40 mg/m2 will be instilled into the peritoneal cavity through the IP port on days 1 and 8, repeated every 21 days for 3 months (3-4 cycles). Restaging imaging with CT and /or diffusion weighted MRI with contrast will be obtained 4-6 weeks after completion of IP chemotherapy. Based on response and extent of disease, patients will be triaged to one of the following treatment plans: stable disease or response and PCI >10 - continue IP chemotherapy regimen, progression - switch to second line regimen, response with PCI ≤ 10 and complete cytoreduction is feasible - consider cytoreduction surgery (CRS) with intraperitoneal chemotherapy (IPEC).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This clinical trial is a non-randomized, open label, single arm clinical trial.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis (STOPGAP)
Actual Study Start Date : February 18, 2021
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SingleArm: Systemic therapy and IP Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis
Patients will receive sequential intraperitoneal paclitaxel along with intravenous paclitaxel, 5-FU, and leucovorin on Days 1 and 8 of every 21 day cycle for 3 months.
Drug: Paclitaxel
Intraperitoneal Paclitaxel

Drug: Paclitaxel
IV Paclitaxel

Drug: Leucovorin
IV Leucovorin

Drug: Fluorouracil
Other Name: 5-FU

Primary Outcome Measures :
  1. Participants with Progression Free Survival at 1-Year [ Time Frame: 1 year ]
    Progression-free survival is defined as the duration of time from start of systemic treatment to time of progression, death, or clinical deterioration attributed to disease progression as judged by the investigator. Radiographic progression is defined using the Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm and/or appearance of new lesions.

  2. Incidence of Treatment-Emergent Adverse Events [Safety] [ Time Frame: From date of study treatment initiation to first date of disease progression, toxicity, delay of treatment, or withdrawal of treatment, assessed up to 12 months after the last patient is enrolled. ]
    To evaluate the safety of IP paclitaxel and IV paclitaxel, 5-FU, and leucovorin in patients with primary gastric/GEJ adenocarinoma with peritoneal carcinomatosis determined by the incidence of treatment-emergent adverse events. Adverse events are based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 5.0.

Secondary Outcome Measures :
  1. Overall Survival of Participants [ Time Frame: From initiation of systemic treatment to up to 12 months after last patient is enrolled or until death from any cause. ]
    To assess the overall survival of participants from the start of systemic treatment to the death from any cause.

  2. Patient Reported Quality of Life Outcomes [ Time Frame: From initiation of study treatment until patient is off study, assessed up to 12 months after the last patient has started treatment. ]
    To assess the quality of life of participants such as mobility, self-care, daily activities, pain/discomfort and anxiety/depression and a visual analog scale (VAS). VAS consists of endpoints labeled best imaginable health status at the top and worse imaginable health state at the bottom having numeric values of 100 and 0 respectively.

Other Outcome Measures:
  1. Expression of Plasma and Ascites Exosomal Gene Signature (EXOSIG) [ Time Frame: From date of registration to up to 12 months after last patient is enrolled. ]
    To assess the expression of plasma and ascites exosomal gene signature (EXO SIG) in patients with gastric cancer peritoneal carcinomatosis compared to healthy controls.

  2. Correlation of Plasma and Ascite Exosomal Gene Signature (EXOSIG) to Treatment Response [ Time Frame: From date of registration to up to 12 months after last patient is enrolled. ]
    To assess the correlation of changes in exosomal gene signature to treatment response in patients with gastric cancer peritoneal carcinomatosis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed primary gastric or gastroesophageal adenocarcinoma and have received a minimum of three months of first line systemic treatment without visceral metastatic progression
  • Must have peritoneal cytology positive disease or peritoneal carcinomatosis detected by imaging, laparoscopy or laparotomy
  • Age ≥ 18 -75 years
  • Performance status: ECOG performance status ≤ 2 (Appendix A) . ECOG 2 allowed is attributed to malignancy (rather than comorbidities)
  • Life expectancy of greater than 6 months
  • Adequate organ and marrow function as defined below:

    1. Leukocytes: ≥ 2,000/mcL
    2. Absolute Neutrophil Count: ≥ 1,500/mcL
    3. Platelets: ≥ 80,000/mcL
    4. Total Bilirubin: within normal institutional limits
    5. AST(SGOT)/ALT(SPGT): ≤5 X institutional upper limit of normal
    6. Creatinine: < 1.5 X institutional upper limit of normal
    7. Hemoglobin: > 8.0 g/dL (may be transfused)
    8. Serum albumin: ≥ g/dL
  • Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

  • Systemic treatment for unresectable or metastatic disease for more than three months prior to enrollment
  • Any evidence of distant, solid organ metastases (visceral (liver, lung, brain), bone, extra-abdominal)
  • Any evidence of extensive retroperitoneal lymph node metastases not amenable to resection during gastrectomy
  • Any evidence of small or large bowel obstruction with the exception of gastric outlet obstruction due to primary malignancy
  • Uncontrolled intercurrent illness including, but not limited to, the following conditions:

    1. Ongoing or active infection
    2. Symptomatic congestive heart failure
    3. Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event,) within 3 months before initiation of treatment
    4. Unstable angina pectoris
    5. Cardiac arrhythmia
  • History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ and not treated with systemic therapy.
  • Inability to comply with study and follow-up procedures as judged by the Investigator
  • Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Has an active infection requiring systemic therapy.
  • Prior surgery that would preclude safe diagnostic laparoscopy and port placement
  • Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04762953

Layout table for location contacts
Contact: Chao Family Comprehensive Cancer Center University of California, Irvine 1-877-827-7883
Contact: University of California, Irvine Medical Center

Layout table for location information
United States, California
Chao Family Comprehensive Cancer Center, University of California, Irvine Recruiting
Orange, California, United States, 92868
Contact: Maheswari Senthil, MD    877-827-8839   
Sponsors and Collaborators
University of California, Irvine
Layout table for investigator information
Principal Investigator: Maheswari Senthil, MD Chao Family Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Maheswari Senthil, MD, Clinical Professor, University of California, Irvine Identifier: NCT04762953    
Other Study ID Numbers: UCI 20-87 [HS#2020-6178]
2020-6178 ( Other Identifier: University of California, Irvine )
First Posted: February 21, 2021    Key Record Dates
Last Update Posted: March 9, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Maheswari Senthil, MD, University of California, Irvine:
Gastric Cancer
Peritoneal Carcinomatosis
Gastroesophageal Junction (GEJ) Adenocarinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Peritoneal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Abdominal Neoplasms
Peritoneal Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs